A study of symptoms described by ovarian cancer survivors

Chara Stavraka(King's College London), Sarah P. Blagden(Churchill Hospital), Sadaf Ghaem‐Maghami(Hammersmith Hospital), Amy Ford(Ovarian Cancer Action), Tim Crook(St. Mary's Hospital), Roshan Agarwal(Imperial College Healthcare NHS Trust), Hani Gabra(Royal Children's Hospital)

Gynecologic Oncology

December 11, 2011

10.1016/j.ygyno.2011.12.421

Cited by 94

Related Papers

Rethinking ovarian cancer: recommendations for improving outcomes

|Nature reviews. Cancer|2011|1.5k

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

|Nature reviews. Cancer|2015|1.4k

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

|The Lancet|2019|223

Performance status score: do patients and their oncologists agree?

|British Journal of Cancer|2003|222

La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs

|eLife|2017|201